Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy

BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Circulation
Main Authors: Kazi, Dhruv S., Bellows, Brandon K., Baron, Suzanne J., Shen, Changyu, Cohen, David J., Spertus, John A., Yeh, Robert W., Arnold, Suzanne V., Sperry, Brett W., Maurer, Mathew S., Shah, Sanjiv J.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/
https://ncbi.nlm.nih.gov/pubmed/32078382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker